mitomycin has been researched along with Margins of Excision in 3 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Margins of Excision: The edges of tissue removed in a surgery for assessment of the effectiveness of a surgical procedure in achieving the local control of a neoplasm and the adequacy of tumor removal. When the margin is negative or not involved by tumor (e.g., CANCER) it suggests all of the tumor has been removed by the surgery.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC)." | 3.91 | Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. ( Abe, Y; Aiura, K; Endo, Y; Fukada, J; Hori, S; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Nakano, Y; Oshima, G; Shinoda, M; Yagi, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Endo, Y | 1 |
| Kitago, M | 1 |
| Aiura, K | 1 |
| Shinoda, M | 1 |
| Yagi, H | 1 |
| Abe, Y | 1 |
| Oshima, G | 1 |
| Hori, S | 1 |
| Nakano, Y | 1 |
| Itano, O | 1 |
| Fukada, J | 1 |
| Masugi, Y | 1 |
| Kitagawa, Y | 1 |
| Bußmann, L | 1 |
| Laban, S | 1 |
| Wittekindt, C | 1 |
| Stromberger, C | 1 |
| Tribius, S | 1 |
| Möckelmann, N | 1 |
| Böttcher, A | 1 |
| Betz, CS | 1 |
| Klussmann, JP | 1 |
| Budach, V | 1 |
| Muenscher, A | 1 |
| Busch, CJ | 1 |
| Russo, S | 1 |
| Anker, CJ | 1 |
| Abdel-Wahab, M | 1 |
| Azad, N | 1 |
| Bianchi, N | 1 |
| Das, P | 1 |
| Dragovic, J | 1 |
| Goodman, KA | 1 |
| Jones, W | 1 |
| Kennedy, T | 1 |
| Kumar, R | 1 |
| Lee, P | 1 |
| Sharma, N | 1 |
| Small, W | 1 |
| Suh, WW | 1 |
| Jabbour, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer[NCT03691441] | Phase 4 | 280 participants (Anticipated) | Interventional | 2018-01-05 | Active, not recruiting | ||
| Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients[NCT05060471] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-09-08 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitomycin and Margins of Excision
| Article | Year |
|---|---|
Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecitabine; Carcinoma, | 2019 |
1 trial available for mitomycin and Margins of Excision
| Article | Year |
|---|---|
Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cause of Death; Chemoradiotherapy, Adjuvant; | 2020 |
1 other study available for mitomycin and Margins of Excision
| Article | Year |
|---|---|
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |